Search Results
Nov 17, 2025, 08:05 ET New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
comorbidities such as obesity, cardiovascular disease, anxiety and depression are often present.16 Studies show up to 30% of people with plaque PsO also develop PsA.10 ABOUT TREMFYA® (guselkumab)Developed by Johnson &
More news about: Johnson & Johnson
Nov 12, 2025, 15:07 ET Northern Arizona Healthcare Wins National Patient Safety Award
Center by the U.S. Agency for Healthcare Research and Quality and a federally certified Patient Safety Organization (PSO) by the U.S. Department of Health and Human Services. The ECRI and ISMP PSO maintains the largest national patient safety reporting and learning system—collecting and analyzing more than
More news about: ECRI
Oct 29, 2025, 06:57 ET AEP Reports Third-Quarter 2025 Operating Earnings, Updated Capital Plan Drives New Long-Term Growth Rate
Represents the impact of receiving IRS PLRs related to NOLCs in retail ratemaking on I&M, PSO and SWEPCo. Amount includes a reduction in Excess ADIT and activity related to prior periods
More news about: American Electric Power
Oct 25, 2025, 11:00 ET BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
tissues, with IL-17F increasing over time.1,23-25 IL-17F is over-expressed in skin and highly elevated in the serum of patients with psoriasis (PSO), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), ankylosing spondylitis (AS), and hidradenitis suppurativa (HS).1,23-26
More news about: UCB
Oct 24, 2025, 08:00 ET Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
oral peptide that precisely blocks the IL-23 receptor, in adults and pediatric patients 12 years of age and older (adolescents) with plaque psoriasis (PsO) affecting high-impact sites.
More news about: Johnson & Johnson
Oct 24, 2025, 06:45 ET Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis
hidradenitis suppurativa. Lilly is also advancing novel science to explore the potential of incretins in dermatology and has initiated the TOGETHER-PsO trial investigating the efficacy and safety of treating adults with moderate-to-severe plaque psoriasis and obesity with both ixekizumab and an incretin-based
More news about: Eli Lilly and Company
Oct 24, 2025, 06:45 ET Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
hidradenitis suppurativa. Lilly is also advancing novel science to explore the potential of incretins in dermatology and has initiated the TOGETHER-PsO trial investigating the efficacy and safety of treating adults with moderate-to-severe plaque psoriasis and obesity with both ixekizumab and an incretin-based
More news about: Eli Lilly and Company
Oct 21, 2025, 11:32 ET ISMP Awarded FDA Contract to Support Medication Error Prevention
safety standards. Together, ISMP and ECRI have decades of experience in medication and patient safety, and the ECRI and ISMP Patient Safety Organization (PSO) helps drive improvements using healthcare's largest adverse event dataset. "Medication errors remain one of the most persistent
More news about: Institute for Safe Medication Practices
Sep 29, 2025, 08:00 ET U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
diseases." The plaque PsO approval was based on results from the Phase 3 PROTOSTAR study in pediatric patients with moderate to severe plaque PsO and supportive data from the Phase 3 VOYAGE 1 and 2 studies in adult patients with moderate to severe plaque PsO. In the PROTOSTAR study, the co-primary
More news about: Johnson & Johnson
Sep 26, 2025, 08:55 ET NYSE Content Advisory: Pre-Market Update + Wall Street digests August PCE data
patented drugs, will take effect on October 1st.Opening BellPearson (NYSE: PSO) celebrates the 25th anniversary of listing Closing BellRonald McDonald House NY celebrates National Go Gold
More news about: New York Stock Exchange
Sep 23, 2025, 08:35 ET HKeyBio Lauched the Most Comprehesive Non-human Primate Autoimmune & Allergic Disease Model Matrix to Redefining Clinical Translation
Arthritis (RA), Systemic Sclerosis (SSc), Multiple Sclerosis (MS), Atopic Dermatitis (AD), urticaria, pruritus, Hidradenitis Suppurativa (HS), Psoriasis (Pso), asthma, Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis (IPF), Ulcerative Colitis (UC), and Crohn's Disease (CD).
More news about: HKeyBio
Sep 17, 2025, 08:00 ET Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
Phase 3 RCTs evaluating the efficacy and safety of icotrokinra compared with placebo and deucravacitinib in participants with moderate-to-severe plaque PsO with PASI 90 and IGA score of 0/1 with at least a 2-grade improvement as co-primary endpoints.b. Drs. Soung and Stein
More news about: Johnson & Johnson
Sep 17, 2025, 07:00 ET BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
Congress in Paris, France, September 17-20. These abstracts are part of the 19 presentations from UCB across BIMZELX in PSO, hidradenitis suppurativa, PsA, and axial spondyloarthritis, as well as the abstract for the investigational therapy galvokimig in atopic dermatitis.†
More news about: UCB
Sep 17, 2025, 07:00 ET BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints
tissues, with IL-17F increasing over time.2,16-18 IL-17F is over-expressed in skin and highly elevated in the serum of patients with psoriasis (PSO), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), ankylosing spondylitis (AS), and hidradenitis suppurativa (HS).2,16-19
More news about: UCB
Sep 16, 2025, 14:21 ET Improving Maternal Care Remains Critical in U.S.
maternal deaths for every 100,000 live births, an increase from the previous year. Safety Sprint: Maternal Care ECRI and the ISMP PSO conducted a safety sprint aimed at helping healthcare providers implement best practices for safe maternal care transitions, including transfers between
More news about: ECRI
Sep 10, 2025, 08:00 ET Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care
tissues, with IL-17F increasing over time.8,18-20 IL-17F is over-expressed in skin and highly elevated in the serum of patients with psoriasis (PSO), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), ankylosing spondylitis (AS), and hidradenitis suppurativa (HS).18-21
More news about: UCB